INTERNATIONAL SYMPOSIUM ON HODGKIN LYMPHOMA

11ᵗʰ International Symposium on Hodgkin Lymphoma

 

27-29 October 2018 Cologne
Close
N. Poster
Poster title
Applicant name
Status
  P-001 Hodgkins Variant of Richter Transformation in the Czech Republic Heidi Mocikova Received Received
  P-002 Development of an a-CD30 Bispecific Antibody Immunotherapy for Hodgkin Lymphoma Cindy Schwartz Received Received
  P-003 Microsatellite and chromosomal instability constitute two mechanisms that independently lead to genomic instability in Hodgkin lymphoma. Radhia Mkacher Received Received
  P-004 Array-based DNA methylome analyses of classical Hodgkin lymphoma Julia Vogt Received Received
  P-005 The role of TCF3 in classical Hodgkin lymphoma Rianne Veenstra Received Received
  P-006 Exportin-1 E571K mutation is a common finding in patients with Hodgkin Lymphoma Almudena Navarro-Bailón Received Received
  P-007 TARC immunohistochemistry in the diagnosis of classical Hodgkin lymphoma Arjan Diepstra Received Received
  P-009 CD2 is an important adhesion molecule in the initial interaction between Hodgkin Reed-Sternberg cells and rosetting T cells Johanna Veldman Received Received
  P-010 A new reliable and highly specific antibody to detect SOCS1 (Silencer of Cytokine Signaling 1). Stephanie Ellen Weissinger Received Received
  P-012 Soluble cytokines in Hodgkin lymphoma patients treated with a GHSG policy: an analysis of the Czech Hodgkin Lymphoma Study Group VIT PROCHAZKA Received Received
  P-014 CD47 is expressed on Hodgkin Reed Sternberg cells in Classical Hodgkin lymphoma. Brenda Lopez Pereira Received Received
  P-015 Characterization of T-cell phenotypes with clinical significance in patients with classical Hodgkin lymphoma Kristiina Karihtala Received Received
  P-016 Phenotypic characterization of circulating T and NK cells in classical Hodgkin lymphoma patients in relation to tumor burden and treatment Tom Mulder Received Received
  P-017 Immunologic Biomarkers of Response and Resistance to Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Joo Song Received Received
  P-020 Extracellular ciruculating DNA in Hodgkins lymphoma patients: biological corellates and prognostic impact Dino Dujmovic Received Received
  P-021 Copy number aberrations in cell-free DNA of Hodgkin lymphoma Lieselot Buedts Received Received
  P-022 The Tumor Suppressor SAMHD1 is Downregulated by MYC in Classical Hodgkin Lymphoma George Rassidakis Received Received
  P-023 Conventional vs multifractionation at radiotherapy for above diaphragm stage II Hodgkin Lymphoma: 30-year experience of single Center Nikolai Ilyin Received Received
  P-024 Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity David Straus Received Received
  P-026 Interim- PET Results for Prognosis in Patients with Hodgkin Lymphoma: A Prognostic Factor Exemplar Review (Preliminary Results) Angela Aldin Received Received
  P-027 Cardiovascular Radiation Dosimetry and Predicted Cardiovascular Risks from Involved Field Radiotherapy within the UK RAPID Trial in Early Low-Risk Hodgkin Lymphoma David Cutter Received Received
  P-028 Patterns of Relapse in Patients Treated for Early Stage Classical Hodgkin Lymphoma in the Modern Era Karin Nielsen Received Received
  P-029 Quality Assurance of Involved-Node Radiotherapy: First Results of the HD17-Trial of the GHSG Jan Kriz Received Received
  P-031 Evaluation of CCL17 (TARC) as a diagnostic biomarker for classic Hodgkin lymphoma: interim results from the CANDEL study Annette Lake Received Received
  P-032 Audit of lymphoma patient group irradiated blood product policy compliance at a UK comprehensive cancer centre Jane Gibson Received Received
  P-033 SINGLE CENTER ANALYSIS OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: FOCUS ON R-ABVD AND INTERIM PET Andrea Visentin Received Received
  P-034 Returning to school or work after Hodgkin lymphoma: An EORTC-LYSA cross-sectional study Maja Maraldo Received Received
  P-035 Fatigue impairment in Hodgkin and non-Hodgkin lymphoma survivors: A joint EORTC-LYSA cross-sectional survey Nicolas Mounier Received Received
  P-036 Early-Stage Hodgkin Lymphoma (HL) in the Modern Era: Harnessing Simulation Modeling to Delineate Long-Term Patient Outcomes Andrew Evens Received Received
  P-037 The pathway to diagnosis of Hodgkin Lymphoma in South Africa: the determinants and impact of diagnostic delay Katherine Antel Received Received
  P-038 Hepatitis B virus infection is not associated with poor prognosis in Hodgkin lymphoma patients: A case-control study Weiping Liu Received Received
  P-039 Treatment-related incidence of diseases of the circulatory system (DCS) in patients diagnosed with Hodgkin lymphoma Caroline Weibull Received Received
  P-040 Clinicopathological features and prognosis of 387 cases with classical Hodgkin lymphoma from China Mingzi Yang Received Received
  P-042 Anemia has a negative impact on the outcome of patients with Hodgkin lymphoma Weiping Liu Received Received
  P-043 Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: A retrospective study of 27 cases Mingzi Yang Received Received
  P-044 Investigation the role of adding a serum biomarker to interim PET/CT in Hodgkin lymphoma patients Ádám Jóna Received Received
  P-045 Hyperlipoproteinemia and markers of atherosclerosis in long-term survivors of Hodgkin lymphoma in childhood or adolescence and in healthy controls Michaela Cepelova Received Received
  P-046 No clinical signals of Drug Drug interaction of NEPA (netupitant palonosetron) in cHL patients receiving ABVD regimen: a single-center real life experience VITTORIO ZILIOLI Received Received
  P-047 An Epidemiological Study of Hodgkins Lymphoma from a tertiary care centre in India with study of disease outcome ANKITA SEN Received Received
  P-048 Mature oocytes cryopreservation: a feasible fertility preservation technique in adult Hodgkin lymphoma female patients. Simonetta Viviani Received Received
  P-050 Clinical Characteristics and Prognosis Analysis of Early-Stage Classical Hodgkin Lymphoma Yanfei Liu Received Received
  P-054 Pregnancy in patients in complete remission after Hodgkin Lymphoma: clinical features and outcome. Francesco Gaudio Received Received
  P-055 Health-Related Quality of Life (HRQL) Trajectories during Treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL) Angie Rodday Received Received
  P-058 Fertility in Hodgkins lymphoma patients after initial therapy at Santa Casa de São Paulo Medical School Maria Fernanda Simes Received Received
  P-059 AA Amyloidosis Causing Nephrotic Syndrome in Two Patients with Hodgkin Lymphoma Ayse Salihoglu Received Received
  P-061 Chemotherapy-induced polyneuropathy in patients with Hodgkin lymphoma treated with vinca-alkaloids Lenka Smardova Received Received
  P-062 Distribution of hospital care among paediatric and young adult Hodgkin lymphoma survivors a population-based cohort study from Sweden and Denmark Annika Englund Received Received
  P-064 Cause-specific mortality among Hodgkin lymphoma survivors up to 35 years after treatment Simone de Vries Received Received
  P-065 Elevated neutrophil-to-monocyte ratio is associated with decreased overall survival at 5 years in classic Hodgkin lymphoma Carolina Afonso Received Received
  P-066 eBEACOPP FOR FRONT-LINE TREATMENT OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (cHL) IN THE REAL WORLD SETTING Igor Aurer Received Received
  P-067 VERY LATE RELAPSES (VLRS) IN HODGKIN LYMPHOMA (HL) OCCURING =5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY RADIOTHERAPY (CTRT): PATTERN OF RISK OVER 35 YEARS AND THE SIGNIFICANCE OF HISTOLOGY Theodoros Vassilakopoulos Received Received
  P-068 JUNB, DUSP2, SGK1, CREBBP and SOCS1 are frequently mutated in T-cell/histiocyte rich large B-cell lymphoma Bianca Schuhmacher Received Received
  P-069 EVALUATION OF CLINICAL CHARACTERISTICS IN PATIENTS WITH INTERIM-PET NEGATIVE BUT POSITIVE END OF TREATMENT PET. DATA FROM THE PROSPECTIVE HD08-01 FIL STUDY. Luigi Rigacci Received Received
  P-070 HIV-Associated Hodgkin Lymphoma at Groote Schuur Hospital, Cape Town, South Africa Jessica Opie Received Received
  P-071 A Multicenter Phase 2 Study of Sequential Brentuximab Vedotin and AVD Chemotherapy for Older Patients with Untreated Classical Hodgkin Lymphoma Andrew Evens Received Received
  P-073 BEACOPP escalated increases progression free survival in advanced classic Hodgkin lymphoma - a single centre real life experience Adriana Roque Received Received
  P-077 Comparison immunoarchitectural patterns of primary, extranodal and bone marrow lesions in nodular lymphocyte predominant Hodgkin lymphoma. Irina Shupletsova Received Received
  P-078 Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease Shunan Qi Received Received
  P-079 German evidence-based guideline update on diagnosis, therapy and follow-up of adult Hodgkin lymphoma patients Tina Jakob Received Received
  P-080 Analysis of outcomes and prognostic factors of 165 newly diagnosed patients with advanced classical Hodgkin lymphoma liya A Received Received
  P-081 A Clinicopathologic Consensus Study of Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-cell Lymphoma (DLBCL) and Classical HL (cHL) Andrew Evens Received Received
  P-082 Clinical significance of autoimmune hemolytic anaemia and autoimmune thrombocytopenia during the course of Hodgkin lymphoma Laszlo Imre Pinczes Received Received
  P-083 Low-dose consolidative mediastinal irradiation in accelerated hyperfractionated regimen for advanced Hodgkin lymphoma Tatiana I. Bogatyreva Received Received
  P-084 Brentuximab-Vedotin and Bendamustine as first-line treatment of Hodgkin lymphoma in the elderly (HALO trial). Andrea Gallamini Received Received
  P-086 Metabolic Tumour Volume for Response Prediction inAdvanced-Stage Hodgkin Lymphoma Jasmin Mettler Received Received
  P-090 PET-CT as a prognostic factor in patients with advanced stages in primary diagnosed Hodgkin Lymphoma (HL). Olga Novosad Received Received
  P-092 Proteomic identification of plasma biomarkers in children and adolescents with recurrent Hodgkin Lymphoma Ombretta Repetto Received Received
  P-093 HOPE to COPE with OPPA/COPP: Experience of GPOH HD-2002 study protocol in Pediatric Hodgkin Lymphoma in a tertiary care hospital in a resource constraint setting Pritish Chandra Patra Received Received
  P-095 Hodgkins Lymphoma in adolescents: the Italian Association of Pediatric Hematology and Oncology (AIEOP) experience. Roberta Burnelli Received Received
  P-097 Implementing an effective pre-accrual quality assurance programme in the UK to ensure accuracy and consistency of radiotherapy contouring for paediatric Hodgkins Lymphoma within the EuroNet-PHL-C2 trial (EudraCT 2012-004053-88) Patricia Diez Received Received
  P-104 Nivolumab in relapsed/refractory classic Hodgkin lymphoma: Experience with ten patients Reyad Dada Received Received
  P-105 A PHASE II STUDY OF PEMBROLIZUMAB (PEM) FOLLOWED BY AVD FOR FRONTLINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA (CHL): INTERIM RESULTS Pamela Allen Received Received
  P-106 Clinical benefit of Nivolumab in Hodgkin Lymphoma but at what price? Example into a Paris University Hospital Elodie Peyrilles Received Received
  P-108 Allogeneic stem cell transplantation after treatment with checkpoint inhibitors: feasibility and safety in pooled analysis Reyad Dada Received Received
  P-110 Successful treatment of Hodgkin lymphoma with brentuximab vedotin relapsing after autologous stem cell transplantation Jana Markova Received Received
  P-111 Time to relapse in nodular lymphocyte-predominant Hodgkin lymphoma is related to the histopathological pattern at initial diagnosis and relapse Sylvia Hartmann Received Received
  P-112 A PHASE II STUDY WITH BENDAMUSTINE PLUS BRENTUXIMAB VEDOTIN IN HODGKINS LYMPHOMA IN FIRST SALVAGE SETTING: THE BBV REGIMEN. Alessandro Broccoli Received Received
  P-113 Phase I/II study of Brentuximab Vedotin in first refractory/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Aspasia Stamatoullas Received Received
  P-114 Mini-BEAM as second salvage chemotherapy after DHAP based chemotherapy for relapsed or refractory classical Hodgkin lymphoma Wouter Plattel Received Received
  P-115 Brentuximab vedotin (BV) as maintenance or salvage therapy after ASCT for relapsed/refractory (R/R) HL Kameliya Simeonova Received Received
  P-116 EARLY TRANSPLANT RELATED COMPLICATIONS IN HODGKIN LYMPHOMA PATIENTS RECEIVING PD-1 INHIBITORS BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION Chiara De Philippis Received Received
  P-117 BENDAMUSTINE IN HEAVILY PRE-TREATED HODGKIN LYMPHOMA PATIENTS Tatiana I. Bogatyreva Received Received
  P-118 Long Term Safety and Efficacy of Combination of Brentuximab Vedotin and Ipilimumab or Nivolumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412) Catherine Diefenbach Received Received
  P-119 Real life data of brentuximab vedotin use in relapsed/refractory HL in Sweden Christine Jansson Received Received
  P-120 Outcomes and Toxicities after Brentuximab vedotin (BV) Maintenance in Relapsed/Refractory Hodgkin Lymphoma Patient Exposed to BV prior to Autologous Hematopoietic Stem Cell Transplant Gunjan Shah Received Received
  P-121 Sequential time-intensified brentuximab vedotin (BV) followed by gemcitabine, vinorelbine and pegylated liposomal doxorubicine (GVD) as a bridge to autologous transplantation in DHAP resistant relapsed or refractory CD30 lymphoma Skirmante Cernauskiene Received Received
  P-122 BRENTUXIMAB VEDOTIN PRIOR TO ALLOGENEIC TRANSPLANTATION IN HODGKINS LYMPHOMAS REDUCES CHRONIC GVHD WITHOUT WORSENING THE OUTCOME Francesco Gaudio Received Received
  P-124 RETROSPECTIVE REAL-LIFE STUDY OF THE BEGEV (BENDAMUSTINE, GEMCITABINE, VINORELBINE) REGIMEN IN HEAVILY PRETREATED, RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS Antonio Russo Received Received
  P-128 SUCCESFUL SLOW DESENSITIZATION TO BRENTUXIMAB VEDOTIN AFTER ANAPHYLAXIS: 3 CASE REPORTS IN THE BASQUE AUTONOMOUS COMMUNITY Itziar Otero Received Received
  P-129 Clinical analysis of relapse patterns in Hodgkin Lymphoma Michael Oertel Received Received
  P-130 PRIMARY PROGRESSIVE CLASSICAL HODGKIN LYMPHOMA A SINGLE CENTRE EXPERIENCE Carolina Afonso Received Received
  P-132 Patterns and Outcomes with Salvage Treatment for Hodgkin Lymphoma (HL) in the Modern Era: A Real-World Analysis from the Community Oncology Setting in the United States Anita Kumar Received Received
  P-133 PROGNOSTIC VALUE OF (18) F-FLUORODEOXYGLUCOSE-POSITRON EMISION TOMOGRAPHY ON SURVIVAL IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION. Eva Domingo Domenech Received Received
  P-134 Induction therapy with everolimus in combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in patients with relapsed or refractory classical Hodgkin lymphoma: a randomized, placebo-controlled phase I/II trial (HD-R3i) Bastian von Tresckow Received Received
  P-135 Brentuximab-Vedotin Bendamustine : a highly effective salvage treatment un refractory/relapsed patients with Hodgkin Lymphoma Krimo Bouabdallah Received Received
  P-136 Long term outcome of patients with relapsed / refractory Hodgkin lymphoma treated at a single institution over 25 years Joanna Romejko-Jarosinska Received Received
  P-137 TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME OF VERY LATE RELAPSES (VLRs) OCCURRING &8805;5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY RADIOTHERAPY (CTRT) IN HODGKIN LYMPHOMA (HL): A JOINT STUDY FROM TWO REFERRAL CENTERS Theodoros Vassilakopoulos Received Received
  P-138 Long-term High Dose Chemotherapy Before Hematopoietic Stem Cell Transplantation due to Restricted Access to New Therapies Tito Vanelli Received Received
  P-139 Brentuximab vedotin alone and in combination with bendamustine as salvage therapy for primary refractory or relapsed Hodgkin lymphoma: multicentre experience of the Polish Lymphoma Research Group Anna Czyz Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:30, Fri 8:30-15:00
07:44
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

INTERNATIONAL SYMPOSIUM ON HODGKIN LYMPHOMA

11ᵗʰ International Symposium on Hodgkin Lymphoma

 

27-29 October 2018 Cologne
HELP LINE
Manage Orders
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 27/08/2018 TO 27/10/2019
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.ISHL11.2018 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 19/10/2018
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster




PosterSessionOnline
Logo Draft
 
Logo Cert